Information for "Usefulness regarding Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to traditional Remedy"
From EECH Central
Basic information
Display title | Usefulness regarding Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to traditional Remedy |
Default sort key | Usefulness regarding Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to traditional Remedy |
Page length (in bytes) | 3,839 |
Page ID | 1420902 |
Page content language | English (en) |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Page protection
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Edit history
Page creator | Locustrest1 (Talk | contribs) |
Date of page creation | 07:13, 30 April 2024 |
Latest editor | Locustrest1 (Talk | contribs) |
Date of latest edit | 07:13, 30 April 2024 |
Total number of edits | 1 |
Total number of distinct authors | 1 |
Recent number of edits (within past 90 days) | 1 |
Recent number of distinct authors | 1 |